Gemcitabine and continuous infusion of 5-fluorouracil in locally advanced and metastatic pancreatic cancer: a phase I-II study.

Published on May 1, 2004in Anticancer Research1.994
Cristina Oliani15
Estimated H-index: 15
,
M. Padovani2
Estimated H-index: 2
(University of Verona)
+ 6 AuthorsGianluigi Cetto17
Estimated H-index: 17
(University of Verona)
Sources
Abstract
Background: Gemcitabine has been recently recognized as standard treatment in advanced pancreatic cancer. To potentiate its single-agent activity we conducted a phase I-II study with the primary objective of establishing the maximum tolererated dose (MTD) of gemcitabine and continuous infusion 5-FU in patients with locally advanced or metastatic pancreatic cancer. Patients and Methods Fifteen patients received a fixed dose of 5-FU 200 mg/mq protracted infusion for six months. Gemcitabine was administered weekly for three out of four weeks for six cycles at escalating doses of 800 mg/mq to 1100 mg/mq. Results: MTD was established at 1000 mg/mq of gemcitabine. Of the 11 evaluable patients, 7 patients had stable disease, 1 had partial response and 3 had progressive disease. Of the 14 patients evaluable at follow-up, median time to progression was 5 months. Median survival was 10 months. Conclusion: This study confirms the good tolerability of the combination, of gemcitabine with 5-FU. The number of cases of pancreatic cancer in 1990 was 27,000 in Europe and 30,000 deaths are estimated annually (1). Pancreatic cancer is the fifth most common cause of cancer-related mortality in the United States, following lung, colorectal, breast and prostate cancer. It is the fourth leading cause of death from cancer in men and the fifth leading cause of death from cancer in women. There is increased risk after the age of 30, while most commonly appears between the ages of 65 and 79 years. At present there is no known cause for the disease; however, it has been linked to cigarette smoking, socioeconomic status, alcohol consumption, chronic pancreatitis and diabetes (2). Chemotherapy has been proposed in the past, but in clinical studies different drugs and regimens have
📖 Papers frequently viewed together
4,708 Citations
References26
Newest
#1Werner Scheithauer (University of Vienna)H-Index: 55
#2B. Schüll (University of Vienna)H-Index: 15
Last. G.V. Kornek (University of Vienna)H-Index: 22
view all 11 authors...
Background: Gemcitabine is an active antitumor agent in the treatment of advanced pancreatic cancer, and has shown potential synergistic activity with the oral fluoropyrimidine capecitabine in previous phase I/II trials. Based on this background and in order to define the therapeutic potential and tolerance of this combination more precisely, the present randomized multicenter phase II trial was initiated. Patients and methods: We prospectively randomized 83 patients to treatment with biweekly g...
168 CitationsSource
#1Jordan Berlin (Vandy: Vanderbilt University)H-Index: 67
#2Paul J. Catalano (Vandy: Vanderbilt University)H-Index: 73
Last. Al B. Benson (Vandy: Vanderbilt University)H-Index: 121
view all 6 authors...
PURPOSE: Gemcitabine is generally considered to constitute first-line therapy for pancreatic cancer. To determine whether the addition of fluorouracil (5-FU) improves on the results from single-agent gemcitabine, the Eastern Cooperative Oncology Group (ECOG) compared gemcitabine plus bolus 5-FU with gemcitabine alone for patients with advanced pancreatic carcinoma. PATIENTS AND METHODS: This trial involved patients with biopsy-proven, advanced carcinoma of the pancreas not amenable to surgical r...
673 CitationsSource
#1C. LouvetH-Index: 31
#2Thierry AndréH-Index: 80
Last. A. de GramontH-Index: 44
view all 10 authors...
PURPOSE: Based on preclinical in vitro synergy data, this study evaluated the activity and toxicity of a gemcitabine/oxaliplatin combination in patients with metastatic and locally advanced pancreatic adenocarcinoma. PATIENTS AND METHODS: Previously untreated metastatic and locally advanced unresectable pancreatic adenocarcinoma patients were enrolled onto this multicenter phase II study. Patients received gemcitabine 1,000 mg/m2 as a 10-mg/m2/min infusion on day 1 and oxaliplatin 100 mg/m2 as a...
202 CitationsSource
Abstract Purpose: The current standard local treatment for nonresectable pancreatic carcinoma is radiotherapy (RT) with concurrent 5-fluorouracil (5-FU); however, the optimal schedule for 5-FU administration has not been fully established. In this study, we report on our experience with the combination of RT and continuous infusion 5-FU in a group of patients with locally nonresectable pancreatic carcinoma. Methods and Materials: Forty-two patients with adenocarcinoma of the pancreas were enroll...
47 CitationsSource
#1Philip A. Philip (WSU: Wayne State University)H-Index: 76
#2Mark M. Zalupski (WSU: Wayne State University)H-Index: 51
Last. Anthony F. Shields (WSU: Wayne State University)H-Index: 52
view all 9 authors...
BACKGROUND Pancreatic carcinoma is considered among the most chemoresistant of human malignancies. The most commonly used cytotoxic single agents, 5-fluorouracil and 2′-deoxy-2′,2′-difluorocytidine (gemcitabine), have objective response rates of less than 10% in large studies. Hypothesizing noncross resistance and a synergistic interaction between gemcitabine and cisplatin, early clinical studies have demonstrated significant activity with this combination in patients with several types of malig...
130 CitationsSource
#1Adolfo MarantzH-Index: 2
#2S. Jovtis (Grupo México)H-Index: 5
Last. Francisco LastiriH-Index: 1
view all 15 authors...
The primary goal of this phase II study was to determine the efficacy of gemcitabine (Gemzar; Eli Lilly and Company, Indianapolis, IN) plus 5-fluorouracil in patients with pancreatic cancer. Eligibility criteria included nonresectable locally advanced or metastatic pancreatic adenocarcinoma and measurable disease. Gemcitabine at 1,000 mg/m 2 and leucovorin at 20 mg/m 2 were administered Intravenously 30 minutes before 5-fluorouracil 600 mg/m 2 , weekly for 3 of every 4 weeks. Twenty nine patient...
16 CitationsSource
#1Michele ReniH-Index: 68
#2Paolo PassoniH-Index: 22
Last. Eugenio VillaH-Index: 43
view all 9 authors...
PURPOSE: To evaluate the efficacy and toxicity of a cisplatin, epirubicin, gemcitabine, and fluorouracil (PEF-G) schedule on stage IV pancreatic adenocarcinoma. PATIENTS AND METHODS: Patients ≤ 70 years, with no prior chemotherapy and with bidimensionally measurable stage IV pancreatic adenocarcinoma, Eastern Cooperative Oncology Group performance status ≤ 2, and adequate bone marrow, kidney, and liver function were eligible for this trial. Eligibility criteria for clinical benefit assessment we...
89 CitationsSource
#1C. LouvetH-Index: 31
#2Thierry AndréH-Index: 80
Last. A. de GramontH-Index: 44
view all 12 authors...
Background. Gemcitabine alone or 5-fluorouracil (5-FU) according to several schedules are used for palliation of metastatic and locally advanced (LA) pancreatic adenocarcinoma. This study was designed to test the efficacy of the leucovorin 5-FU and gemcitabine combination. Patients and methods: This phase II trial combined a simplified bimonthly LV5FU2 with gemcitabine: leucovorin 400 mg/m 2 in a two-hour infusion, followed by 5-fluorouracil 400 mg/m 2 bolus and 2 or 3 g/m 2 continuous infusion ...
40 CitationsSource
#1Caio Max S. Rocha Lima (MUSC: Medical University of South Carolina)H-Index: 5
#1Rocha Lima Cm (MUSC: Medical University of South Carolina)H-Index: 1
Last. Chris Y. BrunsonH-Index: 2
view all 5 authors...
Gemcitabine (Gemzar) and irinotecan (CPT-11, Camptosar) are active cytotoxic drugs against pancreatic cancer. Preclinical data evaluating the combination of gemcitabine and irinotecan suggest dose-dependent synergistic
13 Citations
#1William H. Sherman (Columbia University)H-Index: 40
#2Robert L. FineH-Index: 44
Objective: To determine the clinical and laboratory response rate of a gemcitabine and docetaxel combination in human adenocarcinoma of the pancreas in vitro and in vivo. M
51 CitationsSource
Cited By9
Newest
#1Francesca Saini (University of Nottingham)H-Index: 1
#2Richard H. Argent (University of Nottingham)H-Index: 18
Last. Anna M. Grabowska (University of Nottingham)H-Index: 26
view all 3 authors...
Pancreatic ductal adenocarcinoma (PDAC) is characterised by desmoplasia, thought to support progression and chemotherapeutic resistance. The Hedgehog pathway is known to play an important role in this cancer. While the upregulation of Sonic hedgehog (Shh) in the epithelium of PDAC is known, we investigated its expression in the tumour microenvironment in order to find new targets for new chemotherapeutical approaches. Immunohistochemistry was used for the investigation of Shh and Vimentin in pri...
9 CitationsSource
#1Marianne Melnik (MSU: Michigan State University)H-Index: 6
#2Craig P. Webb (Van Andel Institute)H-Index: 29
Last. Han Mo Koo (Van Andel Institute)H-Index: 8
view all 17 authors...
Prior studies suggest that tumor cell lines harboring RAS mutations display remarkable sensitivity to gemcitabine and etoposide. In a phase II clinical trial of patients with locally advanced or metastatic pancreatic cancer, we evaluated the response rate to a combination of these drugs. Forty chemo-naive patients with nonresectable and histologically confirmed pancreatic cancer were accrued. Patients received gemcitabine 1,000 mg/m2 (days 1 and 8) and etoposide 80 mg/m2 (days 8, 9, and 10; 21-d...
11 CitationsSource
#1Yoshinori NioH-Index: 24
#2Chikage IguchiH-Index: 11
Last. Shinichiro EndoH-Index: 4
view all 11 authors...
Background: Advanced or recurrent pancreatic cancer can sometimes cause obstruction or stenosis of the portal vein (PV), resulting in various symptoms of portal hypertension (PH), such as ascites, pancytopenia, hemorrhagic tendencies and liver dysfunction. We placed an expandable metallic stent into the PV to improve PH- associated complications and liver function. The placement of the PV stent was beneficial for administering chemotherapeutic agents and radiotherapy (RT) safely, and resulted in...
8 Citations
#1Massimo Donadelli (University of Verona)H-Index: 32
#2Chiara Costanzo (University of Verona)H-Index: 21
Last. Marta Palmieri (University of Verona)H-Index: 32
view all 11 authors...
We investigated the ability of the histone deacetylase (HDAC) inhibitor trichostatin A (TSA) to interact with gemcitabine (GEM) in inducing pancreatic cancer cell death. The combined treatment with TSA and GEM synergistically inhibited growth of four pancreatic adenocarcinoma cell lines and induced apoptosis. This effect was associated with the induction of reactive oxygen species (ROS) by GEM, increased expression of the pro-apoptotic BIM gene by both TSA and GEM and downregulation of the 5′-nu...
123 CitationsSource
#1Sunil Krishnan (University of Texas MD Anderson Cancer Center)H-Index: 80
#2Vishal Rana (University of Texas MD Anderson Cancer Center)H-Index: 8
Last. Christopher H. CraneH-Index: 79
view all 13 authors...
BACKGROUND. Although patients with locally advanced pancreatic cancer (LAPC) have an extremely poor prognosis, they are a heterogeneous group. Prognostic factors are inadequately defined for disease-free survival and overall survival in patients with LAPC who are receiving chemoradiation, so more definitive prognostic factors would be very useful for designing clinical trials. METHODS. Between December 1993 and July 2005, 247 patients with nonmetastatic LAPC were treated at M. D. Anderson Cancer...
69 CitationsSource
#1Her Shyong Shiah (NHRI: National Health Research Institutes)H-Index: 9
#2Ann-Lii Cheng (NTU: National Taiwan University)H-Index: 90
Last. Li-Tzong Chen (KMU: Kaohsiung Medical University)H-Index: 54
view all 12 authors...
Background: Pancreatic cancer is a dismal disease. Few drugs, including gemcitabine and 5-fluorouracil (5-FU), have notable antitumor effects against advanced pancreatic cancer. The purpose of the present study was to determine the maximum tolerated dose (MTD) of 5-FU and the efficacy and toxicity profile of weekly gemcitabine plus infusional 5-FU/leucovorin in advanced pancreatic cancer. Methods: Patients with histo-/cytologically confirmed, advanced pancreatic cancer were eligible. Treatment c...
7 CitationsSource
#1Mikael Öman (Umeå University)H-Index: 9
#2Stefan Lundqvist (Umeå University)H-Index: 7
Last. Peter Naredi (Umeå University)H-Index: 29
view all 5 authors...
Background: Systemic palliative treatment with chemotherapy against advanced pancreas cancer has low effectiveness despite considerable toxicity.
10 CitationsSource
#1Gregory Friberg (U of C: University of Chicago)H-Index: 3
#1Gregory Friberg (U of C: University of Chicago)H-Index: 3
Last. Hedy L. Kindler (U of C: University of Chicago)H-Index: 78
view all 2 authors...
Advanced pancreatic cancer is a devastating illness characterized by significant morbidity and a brief median survival. Although standard chemotherapy with gemcitabine achieves only modest improvements in survival and quality of life, classic cytotoxic agents, such as 5-fluorouracil, pemetrexed, irinotecan, exatecan, cisplatin, or oxaliplatin, given alone or in combination with gemcitabine, have not proved superior. Thus, more recent trials have focused on targeting the biologic characteristics ...
19 CitationsSource
Background:Pancreas cancer is a most aggressive malignancy. More than 80% of patients diagnosed with pancreas cancer, exhibit such advanced disease, that curative surgery is impossible. Systemic ch ...